COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

• Status: Active, not recruiting
• Trial end date: 2024-02-22

Summary

COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: MedImmune LLC
• Treatments: Bevacizumab; Durvalumab; Fluorouracil; Folic Acid; Leucovorin; Levoleucovorin; Oxaliplatin